Moderna begins early-stage trial of mRNA Ebola vaccine

Moderna announced the launch of an early-phase clinical trial testing an mRNA vaccine designed to protect against Ebola virus. The study will enroll healthy volunteers to evaluate the vaccine's safety profile and its ability to provoke an immune response.

The trial marks another step in Moderna's broader effort to apply its mRNA platform to infectious diseases beyond COVID-19. While details on the trial size and timeline were not disclosed, the company aims to generate data that could inform later-stage development.

If successful, the program could add a novel tool to the limited arsenal of Ebola countermeasures and demonstrate the versatility of mRNA technology in addressing high‑risk pathogens.